About OncoImmune, Inc.

Based in Rockville, Maryland, OncoImmune is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biopharmaceuticals for the treatment of cancer and autoimmune disease. Founded in 2000 on the scientific discoveries of our founders, we have moved our lead product, CD24Fc, from a basic concept into clinical trials. CD24Fc has a novel mechanism of action that is applicable to a number of autoimmune diseases that has shown good safety and tolerability in a Phase I clinical trial in healthy volunteers. OncoImmune is currently preparing for a Phase II clinical trial of CD24Fc for the prophylactic treatment of acute Graft versus Host Disease (GvHD).

Management Team

Martin Devenport, PhD, MBA

Martin Devenport, PhD, MBA

Chief Operating Officer

Prior to joining OncoImmune, Dr. Devenport was VP for Business Strategy at Amplimmune Inc., where he oversaw all project management and operational activities, as well as business development, contracts and intellectual property. Dr. Devenport is experienced with all aspects of the drug development process, including research, development, GMP manufacturing, regulatory and clinical trials, and has managed a number of biotechnology programs that reached clinical stage development in oncology and autoimmune indications.

Weng Tao, MD, PhD

Weng Tao, MD, PhD

Head of Clinical Affairs

Dr. Tao is a biotech executive with over 20 years of experience in cellular and biologics therapeutic development for unmet medical needs. Prior to joining OncoImmune, Dr. Tao co-founded Neurotech USA in 2000, and served as its Chief Scientific Officer and Vice President for Research and Development, leading the development of their Encapsulated Cell Technology (ECT) from lab concept to clinical testing for a wide range of currently untreatable or under treated diseases, including RP, GA, MacTel and wet AMD. Dr. Tao then went on to start her own biotech consulting company, Tao Consulting LLC. She has broad experience in translational research, clinical development and regulatory affairs and a proven track record in team building, project management and problem solving utilizing multidisciplinary approaches.

Founders & Board of Directors

Yang Liu, PhD (Chairman & Founder)

Dr. Liu is recognized internationally for his research on immune recognition of cancer and activation of lymphocytes, the main immune defender against cancer. He has received the Markey Scholar Award (1992), and the Sears Scholar Award (1993), and Snyder Award for Cancer Research (2015) and was elected to the rank of fellow at the American Association for Advancement of Science (AAAS) in 2004 for his pioneering contribution to Innate Immunity, T cell costimulation and cancer immunology.

Dr. Liu received his Ph.D. from the Australian National University, and postdoctoral fellowship from Yale University. Dr. Liu is currently director for Center for Cancer and Immunology Research at the Children’s National Medical Center and Bosworth Professor for Cancer Biology and Transplantation Immunology at the Department of Pediatrics, Children’s National Medical Center and George Washington University.

Kun-Liang Guan, PhD (Founder)

Dr. Guan is an authority in signal transduction in regulation of cell growth, organ size control and tumorigenesis. He demonstrated the role of Tuberous Sclerosis tumor suppressors in cell growth by inhibiting mTOR and contributed to the establishment of the mTOR signaling network. He discovered the signals and receptors for the elusive Hippo/YAP pathway and revealed the biochemical mechanism of it regulation. Dr. Guan was elected as fellow of AAAS in 2008 for his pioneering contribution to cell biology and signal transduction.

Dr. Guan earned his bachelor from Hangzhou University and Ph.D. from Purdue University. He has won Young Investigator Award from American Society of Biochemistry and Molecular Biology; MacArthur Fellow from the MacArthur Foundation; Distinguished Alumni Award from Purdue University. Dr. Guan is a highly cited researcher in molecular biology and genetics (Thomson Reuter).

Ming You (Founder)

Dr. You joined the Medical College of Wisconsin (MCW) as director of MCW Cancer Center from Washington University in St. Louis in 2010, where he was the Mary Culver Distinguished Professor of Surgery and director of the chemoprevention program at the Alvin J. Siteman Cancer Center. His research interests are in chemoprevention of lung cancer using a variety of novel agents, identification of candidate lung cancer susceptibility genes by capture-sequencing of targeted regions or genes, identification of frequent somatic mutations in lung adenocarcinomas and squamous cell carcinomas by exome sequencing.  He was a member of the Board of Scientific Counselors of the NCI, and was a member of the Chemo/Dietary Prevention Study Section (CDP) and the Chemical Pathology Study Section (CPA) at the NIH. He also served as a member of the NCI’s Cancer Susceptibility Think Tank and Cancer Chemoprevention Think Tank and the chair of the Review Panel for Chemopreventive Agent Development Research Group (CADRG), Division of Cancer Prevention at the NCI. He is an Associate Editor of Cancer Prevention Research and is on the Editorial Board of PLoS One. He served as a member of the editorial boards of Cancer Research and Carcinogenesis. Currently, he serves on the External Scientific Advisory Board for Roswell Park Cancer Institute, an NCI-designated Comprehensive Cancer Center. His publications focus on work in genetics and chemoprevention of lung cancer and his bibliography includes over 230 titles. He have mentored a large number of graduate students and post-doctoral fellows. Hereceived his medical degree in 1982 from Beijing Medical College and his PhD in pathology from the Medical College of Ohio in 1989.

Pan Zheng, MD, PhD (Founder)

Dr. Zheng co-founded OncoImmune, Inc. while she was a faculty at the Ohio State University.  Dr. Zheng is currently an endowed Professor and the McKnew Chair for Cancer Biology at Children’s National Medical Center in Washington, DC, where her lab focuses on the fields of hematopoietic stem cell study, immunology and cancer biology. Dr. Zheng  was trained in anatomic and clinical pathology and is a Board-certified Physician with the American Board of Pathology.

Jeff Wilkins

An experienced business leader and entrepreneur, Mr. Wilkins currently serves as Chief Executive Office of Facilities Management Express, an expansion stage software company and serves on a number of advisory boards in the fields of drug development, telecommunications, and financial services.

During his career Mr. Wilkins founded and led two publicly traded companies, CompuServe Inc. and Metatec International. As CompuServe’s leader, he initiated the global emergence of online information services to personal computer owners and other businesses, including a nationwide telecommunications network for data transmission, the first full-service electronic mail system for business, and custom computer application services to organizations in a variety of markets and industries.  Metatec built the first independently owned optical disc manufacturing facility in the United States.

Mr. Wilkins holds bachelor’s and master’s degrees in electrical engineering from the University of Arizona. He previously served on the boards of Bank One of Columbus, N.A.; H&R Block, Inc.; Liebert Corporation; Cardinal Health, Inc.; Accuray Corporation; Midland Mutual Life Insurance; and The Holophane Corporation. During his tenure as a director of these companies, he participated and advised on numerous acquisition and sale transactions.

© Copyright - OncoImmune